Climb Bio, Inc. (CLYM)

Climb Bio, Inc. (CLYM) scores 21 out of 100 on boothcheck's 11-model valuation framework. Verdict: Strong Avoid The estimated fair value is $0. Quantitative score: 39/100. Qualitative score: 20/100.

Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.

View full CLYM analysis on boothcheck